Gene Mack, CEO, GAIN Therapeutics, outlines how early trial results for GT-02287 are shaping the company’s strategy for ...

In an interview with CNBC, the tech bull said Amazon’s Q2 performance is the “renaissance of growth” that is about to happen ...

The quarter demonstrated consistent customer growth, significant gross margin expansion, and improved operational efficiency, though the pace of revenue growth in synthetic biology slowed. Overall, ...

Double-digit prescription gains for its commercial drugs, major coverage wins, and the early launch of a new migraine therapy were the most significant highlights. Despite substantial progress, the ...

The SEC is moving from case-by-case crypto ETF approvals to a standardized framework, opening the door to broader altcoin ETF ...